Acousia Therapeutics GmbH, a clinical stage biotech company located in Tübingen, Germany, will be presenting their latest clinical study at two upcoming conferences in August and September of 2024. The ACOU085 Phase 2 PROHEAR study will be discussed at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston, Massachusetts from August 20-22, and at the 36th World Congress of Audiology…
No responses yet